LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
BCIQ Data Coverage
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
3rd Biotech CEO & Investor Reception
East-West Biopharma Summit 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Incyclix Bio LLC
Headquarters:
Durham, NC, United States
Website:
https://incyclixbio.com/
Year Founded:
2020
Status:
Private
See
Emerging Company Profile
.
BioCentury
|
Aug 29, 2025
Finance
Three Hong Kong follow-ons signal warming trend: Finance Report
Akeso, Harbour BioMed and Cutia all raise cash via HKSE offerings; plus: Wugen’s nine-digit venture round, and more
Read More
BioCentury
|
Nov 14, 2024
Management Tracks
New CEOs at Valo, Apriori
Plus: Glasspool to lead VarmX, Novartis vet Eissa joins Cellares and updates from Mestag, Andera, Incyclix and more
Read More
BioCentury
|
Aug 22, 2024
Management Tracks
Dimitrios Arkilo named CMO of Actio
Plus: Coya promotes Arun Swaminathan to CEO, and updates from Tempest and Incyclix
Read More
BioCentury
|
Apr 18, 2024
Product Development
CDK2 inhibitors at AACR: An answer to CDK4/6 resistance?
AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types
Read More
BioCentury
|
Apr 2, 2022
Emerging Company Profile
Incyclix Bio: overcoming drug resistance in breast and ovarian cancer
G1 licensee Incyclix is developing molecules selective for a target G1 was trying to avoid
Read More
Items per page:
10
1 - 5 of 5